In continuing pressure to plant its flags around the world, Moderna unveiled plans to set up branches in Hong Kong, Singapore, Taiwan and Malaysia as key regional offices serving the Asian market.
The mRNA player – whose wildly successful Covid-19 vaccine transformed it from a well-known name in biotechnology to a well-known name, period – currently has a limited presence internationally. Its subsidiaries in South Korea, Japan and Australia employ only 24 people in total. Just a few days ago, the news came out that Moderna is finalizing an agreement to build new R&D and production facilities in the UK.
Continue reading Endpoints with a free subscription
Unlock this story right away and join 133,300+ biopharma professionals who read Endpoints daily – and for free.